DOCSLIB.ORG

What's in a Name?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
What's in a Name? What’s in a name? Mitchell J. Weiss, … , Philip J. Mason, Monica Bessler J Clin Invest. 2012;122(7):2346-2349. https://doi.org/10.1172/JCI63989. Commentary Mutations in numerous genes encoding ribosomal proteins (RPs) occur in 50%–70% of individuals with Diamond- Blackfan anemia (DBA), establishing the disease as a ribosomopathy. As described in this issue of JCI, Sankaran, Gazda, and colleagues used genome-wide exome sequencing to study DBA patients with no detectable mutations in RP genes. They identified two unrelated pedigrees in which the disease is associated with mutations in GATA1, which encodes an essential hematopoietic transcription factor with no known mechanistic links to ribosomes. These findings ignite an interesting and potentially emotional debate on how we define DBA and whether the term should be restricted to pure ribosomopathies. More generally, the work reflects the powerful knowledge and controversies arising from the deluge of data generated by new genetic technologies that are being used to analyze human diseases. Find the latest version: https://jci.me/63989/pdf commentaries ognized. While the authors’ findings on 949.824.5626; Fax: 949.824.8598; E-mail: 11. Bockenstedt LK, Mao J, Hodzic E, Barthold SW, Fish D. Detection of attenuated, noninfec- experimental infections of laboratory mice [email protected]. tious spirochetes in Borrelia burgdorferi-infect- may not change opinions on appropriate ed mice after antibiotic treatment. J Infect Dis. antibiotic therapy for patients, they point 1. Simpson J, Weiner E, eds. Oxford English Dictionary. 2002;186(10):1430–1437. to testable hypotheses on the mechanisms 2nd ed. Oxford, United Kingdom: Oxford Univer- 12. Domingue GJ Sr, Woody HB. Bacterial persis- sity Press; 1989. tence and expression of disease. Clin Microbiol Rev. for lingering illness after treatment of 2. Bockenstedt LK, Gonzalez DG, Haberman AM, 1997;10(2):320–344. infection (18, 19) and laboratory means Belperron AA. Spirochete antigens persist near car- 13. Hodzic E, Feng S, Holden K, Freet KJ, Barthold to identify persistent antigenic and mito- tilage after murine Lyme borreliosis therapy. J Clin SW. Persistence of Borrelia burgdorferi following Invest. 2012;122(7):2652–2660. antibiotic treatment in mice. Antimicrob Agents Che- genic stimulation. 3. Barbour AG, Fish D. The biological and mother. 2008;52(5):1728–1736. With PCR and sensitive antigen detec- social phenomenon of Lyme disease. Science. 14. Stricker RB, Johnson L. Lyme disease: the next tion methods so readily at hand, we may 1993;260(5114):1610–1616. decade. Infect Drug Resist. 2011;4:1–9. 4. Tonks A. Lyme wars. BMJ. 2007;335(7626):910–912. 15. Wormser GP, Schwartz I. Antibiotic treatment of neglect more direct but time-consuming 5. Wormser GP, et al. The clinical assessment, animals infected with Borrelia burgdorferi. Clin and artful gauges of viability. Almost 50 treatment, and prevention of lyme disease, Microbiol Rev. 2009;22(3):387–395. years ago, Gutman, Turck, Petersdorf, and human granulocytic anaplasmosis, and babe- 16. Barthold SW, Hodzic E, Imai DM, Feng S, Yang siosis: clinical practice guidelines by the Infec- X, Luft BJ. Ineffectiveness of tigecycline against Wedgwood reported in the JCI the survival tious Diseases Society of America. Clin Infect Dis. persistent Borrelia burgdorferi. Antimicrob Agents of bacterial variants in antibiotic-treated 2006;43(9):1089–1134. Chemother. 2010;54(2):643–651. patients with pyelonephritis (20). They 6. Feder HM Jr, Johnson BJ, O’Connell S, Sha- 17. Embers ME, et al. Persistence of Borrelia burg- piro ED, Steere AC, Wormser GP. A critical dorferi in rhesus macaques following antibiotic used painstaking methods in a pre-PCR appraisal of “chronic Lyme disease”. N Engl J Med. treatment of disseminated infection. PloS One. microbiology lab for “separation of bacteri- 2007;357(14):1422–1430. 2012;7(1):e29914. al variants from classical organisms.” These 7. Marques A. Chronic Lyme disease: a review. Infect 18. Steere AC, Drouin EE, Glickstein LJ. Relationship remains in the urine were uncultivable by Dis Clin North Am. 2008;22(2):341–360. between immunity to Borrelia burgdorferi outer- 8. Cameron D, et al. Evidence-based guidelines for the surface protein A (OspA) and Lyme arthritis. Clin routine procedures but, according to the management of Lyme disease. Expert Rev Anti Infect Infect Dis. 2011;52(suppl 3):s259–s265. authors, lived to cause disease again. Ther. 2004;2(1 suppl):S1–S13. 19. Wormser GP, Nadelman RB, Schwartz I. The 9. Brorson O, Brorson SH. An in vitro study of amber theory of Lyme arthritis: initial description the susceptibility of mobile and cystic forms of and clinical implications. Clin Rheumatol. 2012; Address correspondence to: Alan Barbour, Borrelia burgdorferi to metronidazole. APMIS. 31(6):989–994. Departments of Medicine and Microbiol- 1999;107(6):566–576. 20. Gutman LT, Turck M, Petersdorf RG, Wedgwood ogy & Molecular Genetics, University of 10. Straubinger RK, Summers BA, Chang YF, Appel RJ. Significance of bacterial variants in urine of MJ. Persistence of Borrelia burgdorferi in experi- patients with chronic bacteriuria. J Clin Invest. California Irvine, 3012 Hewitt Hall, Irvine, mentally infected dogs after antibiotic treatment. 1965;44(12):1945–1952. California 92697-4028, USA. Phone: J Clin Microbiol. 1997;35(1):111–116. What’s in a name? Mitchell J. Weiss, Philip J. Mason, and Monica Bessler The Children’s Hospital of Philadelphia, Division of Hematology, Philadelphia, Pennsylvania, USA. Mutations in numerous genes encoding ribosomal proteins (RPs) occur in of chromosome 19 to DBA in a proportion 50%–70% of individuals with Diamond-Blackfan anemia (DBA), establishing of multiplex families (2). Positional cloning the disease as a ribosomopathy. As described in this issue of JCI, Sankaran, revealed that the mutated gene was RPS19, Gazda, and colleagues used genome-wide exome sequencing to study DBA which encodes a protein component of the patients with no detectable mutations in RP genes. They identified two unre- small 40S ribosomal subunit (3). Subse- lated pedigrees in which the disease is associated with mutations in GATA1, quently, RPS19 mutations were identified which encodes an essential hematopoietic transcription factor with no known in approximately 25% of DBA families, all mechanistic links to ribosomes. These findings ignite an interesting and poten- of which showed dominant inheritance. tially emotional debate on how we define DBA and whether the term should be Speculation about how RPS19 mutations restricted to pure ribosomopathies. More generally, the work reflects the pow- might cause DBA ensued for about 10 years. erful knowledge and controversies arising from the deluge of data generated by Specifically, it was debated as to whether the new genetic technologies that are being used to analyze human diseases. disease results from loss of unique extra- ribosomal activities of RPS19 or through The history of DBA precursors and concomitant congenital impaired ribosome production. Support In 1938, pediatricians Louis Diamond and extrahematopoietic anomalies in about for the latter hypothesis emerged when a Kenneth Blackfan described a congenital one-third of patients (1). The etiology of flurry of other DBA genes were identified, anemia with hypoplasia of red blood cell this syndrome, now known as Diamond- all of which encoded different small or large Blackfan anemia (DBA), has fascinated and ribosomal subunit proteins (RPs) (4). perplexed pediatric hematologists for many Conflict of interest: The authors have declared that no conflict of interest exists. years. In 1997, Dahl and colleagues identi- DBA perceived as a ribosomopathy Citation for this article: J Clin Invest. 2012; fied a child with DBA and a X:19 chromo- Currently, 50%–70% of DBA patients are 122(7):2346–2349. doi:10.1172/JCI63989. somal translocation, linking a critical region accounted for by mutations in one of 2346 The Journal of Clinical Investigation http://www.jci.org Volume 122 Number 7 July 2012 commentaries Figure 1 Current model for how RP haploinsufficiency causes DBA. (A) Normal erythroblasts produce large numbers of ribosomes for protein synthesis. Levels of p53 remain low via a feedback loop whereby MDM2, a transcriptional p53 target, ubiquitinates p53 to promote its degradation by pro- teasomes. (B) Haploinsufficiency for specific RPs causes accumulation of other RPs, which bind to MDM2, thereby inhibiting its ability to promote p53 degradation. Consequently, p53 accumulates and triggers cell cycle arrest and apoptosis. 10 RP genes (4, 5). Additional diseases the X chromosome–encoded GATA1 gene. GATA-1, a zinc finger transcription factor in which causative mutations impair By targeted sequencing of an additional 62 expressed mainly in blood cell precursors, is ribosomes include the inherited Treach- male DBA patients, all negative for RP gene essential for the development of red blood er-Collins and Shwachman-Diamond mutations, they identified a second family cells, megakaryocytes and their platelet syndromes and 5q- myelodysplastic syn- with an independent GATA1 gene muta- progeny, mast cells, and eosinophils (10). drome, caused by a somatic chromosomal tion. Both of these mutations alter mRNA Several human blood disorders are caused deletion (4). These disorders illustrate the splicing to favor the production of an by GATA1 mutations that partially reduce concept that genetic alterations in basic amino-truncated GATA-1 protein termed and/or alter function of the corresponding cellular pathways can produce unique GATA-1 short, or GATA-1s. protein (ref. 11 and Figure 2). Germline mis- combinations of organ-specific patholo- gies. How ribosome disruptions lead to DBA is not understood, but a popular theory is that imbalances in individual RPs trigger a p53-mediated checkpoint leading to cell cycle arrest and apoptosis of erythroid precursors (4). In support, certain RPs bind to and inhibit the p53 regulator MDM2 (6). Moreover, in animal models, the DBA-like effects of RP muta- tions depend in part on p53 (refs. 7, 8, Figure 2 and Figure 1).
Load more

Recommended publications
  • Is Swachman-Diamond Syndrome a Ribosomopathy?
    Downloaded from genesdev.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press PERSPECTIVE Of blood, bones, and ribosomes: is Swachman-Diamond syndrome a ribosomopathy? Arlen W. Johnson1,3 and Steve R. Ellis2 1Section of Molecular Genetics and Microbiology, The University of Texas at Austin, Austin Texas 78712, USA; 2Department of Biochemistry and Molecular Biology, University of Louisville School of Medicine, Louisville, Kentucky 40292, USA Mutations in the human SBDS (Shwachman-Bodian-Di- regulation (Ambekar et al. 2010), and stabilizing the amond syndrome) gene are the most common cause of mitotic spindle (Austin et al. 2008). This has led to the Shwachman-Diamond syndrome, an inherited bone mar- suggestion that SBDS is a multifunctional protein, which row failure syndrome. In this issue of Genes & Develop- in turn has led to considerable discussion about which, ment, Finch and colleagues (pp. 917–929) establish that if any, clinical features of SDS are due to defects in SBDS functions in ribosome synthesis by promoting the ribosome production, and which can be attributed to recycling of eukaryotic initiation factor 6 (eIF6) in a GTP- a role for SBDS in other cellular pathways. The study by dependent manner. This work supports the idea that Finch et al. (2011) in this issue of Genes & Development a ribosomopathy may underlie this syndrome. clearly defines a role of SBDS in ribosome synthesis in mammalian cells. This knowledge represents an impor- tant step in ongoing efforts to equate clinical features of SDS with cellular processes affected by loss-of-function Shwachman-Diamond syndrome (SDS) is an inherited mutations in SBDS.
    [Show full text]
  • DKC1 Is a Transcriptional Target of GATA1 and Drives Upregulation of Telomerase Activity Ferrata Storti Foundation in Normal Human Erythroblasts
    Hematopoiesis ARTICLE DKC1 is a transcriptional target of GATA1 and drives upregulation of telomerase activity Ferrata Storti Foundation in normal human erythroblasts Laura A. Richards,1* Ashu Kumari,1* Kathy Knezevic,2 Julie AI Thoms,2,3 Georg von Jonquieres,1 Christine E. Napier,1 Zara Ali,4 Rosemary O’Brien,1 Jonathon Marks-Bluth,2 Michelle F. Maritz,1 Hilda A Pickett,5 Jonathan Morris,6 John E. Pimanda2,3 and Karen L. MacKenzie1,4,7,8 1Children’s Cancer Institute Australia, Randwick; 2Adult Cancer Program, Prince of Wales 3 Haematologica 2020 Clinical School, Lowy Cancer Research Centre, UNSW, Sydney; School of Medical Sciences, UNSW, Sydney; 4Cancer Research Unit, Children’s Medical Research Institute, Volume 105(6):1517-1526 Westmead; 5Telomere Length Regulation Unit, Children’s Medical Research Institute, Westmead; 6The University of Sydney School of Medicine, Kolling Institute of Medical Research, St Leonards; 7School of Women’s and Children’s Health, UNSW, Sydney and 8Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia *LAR and AK contributed equally as co-first authors ABSTRACT elomerase is a ribonucleoprotein complex that maintains the length and integrity of telomeres, and thereby enables cellular proliferation. TUnderstanding the regulation of telomerase in hematopoietic cells is relevant to the pathogenesis of leukemia, in which telomerase is constitu- tively activated, as well as bone marrow failure syndromes that feature telomerase insufficiency. Past studies showing high levels of telomerase in human erythroblasts and a prevalence of anemia in disorders of telomerase insufficiency provide the rationale for investigating telomerase regulation in erythroid cells.
    [Show full text]
  • Translation Factors and Ribosomal Proteins Control Tumor Onset and Progression: How?
    Oncogene (2014) 33, 2145–2156 & 2014 Macmillan Publishers Limited All rights reserved 0950-9232/14 www.nature.com/onc REVIEW Translation factors and ribosomal proteins control tumor onset and progression: how? F Loreni1, M Mancino2,3 and S Biffo2,3 Gene expression is shaped by translational control. The modalities and the extent by which translation factors modify gene expression have revealed therapeutic scenarios. For instance, eukaryotic initiation factor (eIF)4E activity is controlled by the signaling cascade of growth factors, and drives tumorigenesis by favoring the translation of specific mRNAs. Highly specific drugs target the activity of eIF4E. Indeed, the antitumor action of mTOR complex 1 (mTORc1) blockers like rapamycin relies on their capability to inhibit eIF4E assembly into functional eIF4F complexes. eIF4E biology, from its inception to recent pharmacological targeting, is proof-of-principle that translational control is druggable. The case for eIF4E is not isolated. The translational machinery is involved in the biology of cancer through many other mechanisms. First, untranslated sequences on mRNAs as well as noncoding RNAs regulate the translational efficiency of mRNAs that are central for tumor progression. Second, other initiation factors like eIF6 show a tumorigenic potential by acting downstream of oncogenic pathways. Third, genetic alterations in components of the translational apparatus underlie an entire class of inherited syndromes known as ‘ribosomopathies’ that are associated with increased cancer risk. Taken together, data suggest that in spite of their evolutionary conservation and ubiquitous nature, variations in the activity and levels of ribosomal proteins and translation factors generate highly specific effects. Beside, as the structures and biochemical activities of several noncoding RNAs and initiation factors are known, these factors may be amenable to rational pharmacological targeting.
    [Show full text]
  • RPSA, a Candidate Gene for Isolated Congenital Asplenia, Is Required for Pre-Rrna Processing and Spleen Formation in Xenopus John N
    © 2018. Published by The Company of Biologists Ltd | Development (2018) 145, dev166181. doi:10.1242/dev.166181 RESEARCH REPORT RPSA, a candidate gene for isolated congenital asplenia, is required for pre-rRNA processing and spleen formation in Xenopus John N. Griffin1, Samuel B. Sondalle2, Andrew Robson1, Emily K. Mis1, Gerald Griffin1, Saurabh S. Kulkarni1, Engin Deniz1, Susan J. Baserga2,3,* and Mustafa K. Khokha1,2,* ABSTRACT 2004; Henras et al., 2008; Woolford and Baserga, 2013). Production A growing number of tissue-specific inherited disorders are starts in the nucleolus, with transcription of pre-ribosomal RNAs associated with impaired ribosome production, despite the (pre-rRNA), and continues through a series of carefully regulated universal requirement for ribosome function. Recently, mutations in cleavages and ribonucleoparticle assembly steps to ultimately RPSA, a protein component of the small ribosomal subunit, were produce the large 60S ribonucleoprotein subunit (LSU, an discovered to underlie approximately half of all isolated congenital intricate complex of 46 ribosomal proteins and the 28S, 5.8S and asplenia cases. However, the mechanisms by which mutations in this 5S rRNAs) and the small 40S subunit (SSU, 33 ribosomal proteins ribosome biogenesis factor lead specifically to spleen agenesis and the 18S rRNA) (Armistead and Triggs-Raine, 2014; Henras remain unknown, in part due to the lack of a suitable animal model for et al., 2008; Sondalle and Baserga, 2014). Along with cytoplasmic study. Here we reveal that RPSA is required for normal spleen translation factors, the LSU and SSU form a functional ribosome. development in the frog, Xenopus tropicalis. Depletion of Rpsa in It is not surprising that defects in ribosome production or function early embryonic development disrupts pre-rRNA processing and are detrimental to health.
    [Show full text]
  • Ribosomal Protein L10: from Function to Dysfunction
    cells Review Ribosomal Protein L10: From Function to Dysfunction Daniela Pollutri 1,2 and Marianna Penzo 1,2,* 1 Department of Experimental, Diagnostic and Specialty Medicine Alma Mater Studiorum University of Bologna, Via Massarenti 9, 40138 Bologna, Italy; [email protected] 2 Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum University of Bologna, Via Massarenti 9, 40138 Bologna, Italy * Correspondence: [email protected]; Tel.: +39-051-214-3521 Received: 15 October 2020; Accepted: 16 November 2020; Published: 19 November 2020 Abstract: Eukaryotic cytoplasmic ribosomes are highly structured macromolecular complexes made up of four different ribosomal RNAs (rRNAs) and 80 ribosomal proteins (RPs), which play a central role in the decoding of genetic code for the synthesis of new proteins. Over the past 25 years, studies on yeast and human models have made it possible to identify RPL10 (ribosomal protein L10 gene), which is a constituent of the large subunit of the ribosome, as an important player in the final stages of ribosome biogenesis and in ribosome function. Here, we reviewed the literature to give an overview of the role of RPL10 in physiologic and pathologic processes, including inherited disease and cancer. Keywords: RPL10; ribosome; cancer; ribosomopathy; rare disease; translation; protein synthesis 1. Introduction Eukaryotic cytoplasmic ribosomes are highly structured macromolecular complexes made up of four different ribosomal RNAs (rRNAs) and 80 ribosomal proteins (RPs), which play a central role in the decoding of genetic code for the synthesis of new proteins. These two distinct yet complementary functions are separated into the two ribosomal subunits: the 40S (or small) and the 60S (or large) subunits, respectively.
    [Show full text]
  • SCIENCE CHINA the Role of Ribosomal Proteins in the Regulation
    SCIENCE CHINA Life Sciences • REVIEW • July 2016 Vol.59 No.7: 656–672 doi: 10.1007/s11427-016-0018-0 The role of ribosomal proteins in the regulation of cell proliferation, tumorigenesis, and genomic integrity Xilong Xu1, Xiufang Xiong1* & Yi Sun1,2,3‡ 1Institute of Translational Medicine, Zhejiang University School of Medicine, Zhejiang 310029, China; 2Collaborative Innovation Center for Diagnosis and Treatment of Infectious Disease, Zhejiang University, Zhejiang 310029, China; 3Division of Radiation and Cancer Biology, Department of Radiation Oncology, University of Michigan, Ann Arbor MI 48109, USA Received March 15, 2016; accepted April 6, 2016; published online June 12, 2016 Ribosomal proteins (RPs), the essential components of the ribosome, are a family of RNA-binding proteins, which play prime roles in ribosome biogenesis and protein translation. Recent studies revealed that RPs have additional extra-ribosomal func- tions, independent of protein biosynthesis, in regulation of diverse cellular processes. Here, we review recent advances in our understanding of how RPs regulate apoptosis, cell cycle arrest, cell proliferation, neoplastic transformation, cell migration and invasion, and tumorigenesis through both MDM2/p53-dependent and p53-independent mechanisms. We also discuss the roles of RPs in the maintenance of genome integrity via modulating DNA damage response and repair. We further discuss mutations or deletions at the somatic or germline levels of some RPs in human cancers as well as in patients of Diamond-Blackfan ane- mia and 5q- syndrome with high susceptibility to cancer development. Moreover, we discuss the potential clinical application, based upon abnormal levels of RPs, in biomarker development for early diagnosis and/or prognosis of certain human cancers.
    [Show full text]
  • Small and Large Ribosomal Subunit Deficiencies Lead to Distinct Gene Expression Signatures That Reflect Cellular Growth Rate
    Small and Large Ribosomal Subunit Deficiencies Lead to Distinct Gene Expression Signatures that Reflect Cellular Growth Rate The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Cheng, Ze et al. “Small and Large Ribosomal Subunit Deficiencies Lead to Distinct Gene Expression Signatures that Reflect Cellular Growth Rate.” Molecular Cell 73 (2019): 36-47 © 2019 The Author(s) As Published 10.1016/j.molcel.2018.10.032 Publisher Elsevier BV Version Author's final manuscript Citable link https://hdl.handle.net/1721.1/125016 Terms of Use Creative Commons Attribution-NonCommercial-NoDerivs License Detailed Terms http://creativecommons.org/licenses/by-nc-nd/4.0/ HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Mol Cell Manuscript Author . Author manuscript; Manuscript Author available in PMC 2020 January 03. Published in final edited form as: Mol Cell. 2019 January 03; 73(1): 36–47.e10. doi:10.1016/j.molcel.2018.10.032. Small and large ribosomal subunit deficiencies lead to distinct gene expression signatures that reflect cellular growth rate Ze Cheng1, Christopher Frederick Mugler1,2, Abdurrahman Keskin3, Stefanie Hodapp3, Leon Yen-Lee Chan1,2, Karsten Weis2, Philipp Mertins4, Aviv Regev4, Marko Jovanovic3, and Gloria Ann Brar1,*,# 1Department of Molecular and Cell Biology, University of California, Berkeley, CA, 94720, USA 2Department of Biology, Institute of Biochemistry, ETH, CH-8093 Zurich, Switzerland 3Department of Biological Sciences, Columbia University, New York, NY, 10027, USA 4Broad Institute of Harvard and MIT, Cambridge, MA, 02139, USA Summary: Levels of the ribosome, the conserved molecular machine that mediates translation, are tightly linked to cellular growth rate.
    [Show full text]
  • A Novel Ribosomopathy Caused by Dysfunction of RPL10 Disrupts Neurodevelopment and Causes X-Linked Microcephaly in Humans
    HIGHLIGHTED ARTICLE INVESTIGATION A Novel Ribosomopathy Caused by Dysfunction of RPL10 Disrupts Neurodevelopment and Causes X-Linked Microcephaly in Humans Susan S. Brooks,*,1 Alissa L. Wall,†,1 Christelle Golzio,† David W. Reid,‡ Amalia Kondyles,† Jason R. Willer,† Christina Botti,* Christopher V. Nicchitta,‡,§ Nicholas Katsanis,† and Erica E. Davis†,2 *Department of Pediatrics, Rutgers Biomedical and Health Sciences, Robert Wood Johnson Medical School, New Brunswick, New Jersey 08901, and †Center for Human Disease Modeling, ‡Department of Biochemistry, and §Department of Cell Biology, Duke University Medical Center, Durham, North Carolina 27710 ORCID IDs: 0000-0002-1618-7127 (S.B.); 0000-0002-2412-8397 (E.D.) ABSTRACT Neurodevelopmental defects in humans represent a clinically heterogeneous group of disorders. Here, we report the genetic and functional dissection of a multigenerational pedigree with an X-linked syndromic disorder hallmarked by microcephaly, growth retardation, and seizures. Using an X-linked intellectual disability (XLID) next-generation sequencing diagnostic panel, we identified a novel missense mutation in the gene encoding 60S ribosomal protein L10 (RPL10), a locus associated previously with autism spectrum disorders (ASD); the p.K78E change segregated with disease under an X-linked recessive paradigm while, consistent with causality, carrier females exhibited skewed X inactivation. To examine the functional consequences of the p.K78E change, we modeled RPL10 dysfunction in zebrafish. We show that endogenous rpl10 expression is augmented in anterior structures, and that suppression decreases head size in developing morphant embryos, concomitant with reduced bulk translation and increased apoptosis in the brain. Subsequently, using in vivo complementation, we demonstrate that p.K78E is a loss-of-function variant.
    [Show full text]
  • UTR Gata1s Splice Mutation
    The N-terminal domain of human GATA1 prevents dyserythropoietic anemia and megakaryocyte dysplasia in vivo Jacob Zucker1,2, Constance Temm5, Magdalena Czader5 and Grzegorz Nalepa1,2,3,4* 1Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA. 2Division of Pediatric Hematology-Oncology, Bone Marrow Failure Program, Riley Hospital for Children, Indianapolis, Indiana, USA. 3Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA. 4Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA. 5Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. *Corresponding author. Grzegorz Nalepa, Indiana University School of Medicine, Department of Pediatrics, Division of Pediatric Hematology-Oncology, Herman B Wells Center for Pediatric Research, 1044 W. Walnut Street, R4-421, Indianapolis, Indiana 46202, USA. Phone: 317.278.9846; Fax: 317.274.0138; E-mail: [email protected]. Running title: GATA1 5-UTR mutation in human disease Word count: 1193 _________________________________________________________________________________ This is the author's manuscript of the article published in final edited form as: Zucker, J., Temm, C., Czader, M., & Nalepa, G. (2016). A Child With Dyserythropoietic Anemia and Megakaryocyte Dysplasia Due to a Novel 5′UTR GATA1s Splice Mutation. Pediatric Blood & Cancer, 63(5), 917–921. http://doi.org/10.1002/pbc.25871 Key Points 1. Novel germline mutation within the 5’-UTR of GATA1 disrupts splicing of full-length GATA1, causing congenital dyserythropoiesis and megakaryocyte dysplasia 2. Human full-length GATA1 isoform is produced exclusively in erythroblasts and megakaryocytes to orchestrate RBC and platelet production Abstract Inherited mutations in the X-linked hematopoietic transcription factor GATA1 lead to a wide range of blood disorders, from Diamond-Blackfan anemia to myelodysplastic syndrome.
    [Show full text]
  • Molecular Basis of the Human Ribosomopathy Shwachman-Diamond Syndrome
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Apollo Advances in Biological Regulation 67 (2018) 109e127 Contents lists available at ScienceDirect Advances in Biological Regulation journal homepage: www.elsevier.com/locate/jbior Molecular basis of the human ribosomopathy Shwachman- Diamond syndrome * Alan J. Warren a, b, c, a Cambridge Institute for Medical Research, Cambridge, UK b The Department of Haematology, University of Cambridge, Cambridge, UK c Wellcome Trust-Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge, UK article info abstract Article history: Mutations that target the ubiquitous process of ribosome assembly paradoxically cause Received 4 September 2017 diverse tissue-specific disorders (ribosomopathies) that are often associated with an Accepted 5 September 2017 increased risk of cancer. Ribosomes are the essential macromolecular machines that read Available online 6 September 2017 the genetic code in all cells in all kingdoms of life. Following pre-assembly in the nucleus, precursors of the large 60S and small 40S ribosomal subunits are exported to the cyto- Keywords: plasm where the final steps in maturation are completed. Here, I review the recent insights SBDS into the conserved mechanisms of ribosome assembly that have come from functional DNAJC21 eIF6 characterisation of the genes mutated in human ribosomopathies. In particular, recent Shwachman-Diamond syndrome advances in cryo-electron microscopy, coupled with genetic, biochemical and prior Ribosome structural data, have revealed that the SBDS protein that is deficient in the inherited Myelodysplastic syndromes leukaemia predisposition disorder Shwachman-Diamond syndrome couples the final step in cytoplasmic 60S ribosomal subunit maturation to a quality control assessment of the structural and functional integrity of the nascent particle.
    [Show full text]
  • Inflammasome Regulates Hematopoiesis Through Cleavage
    Inflammasome Regulates Hematopoiesis through Cleavage of the Master Erythroid Transcription Factor GATA1 Sylwia Tyrkalska, Ana Pérez-Oliva, Lola Rodríguez-Ruiz, Francisco Martínez-Morcillo, Francisca Alcaraz-Pérez, Francisco Martínez-Navarro, Christophe Lachaud, Nouraiz Ahmed, Timm Schroeder, Irene Pardo-Sánchez, et al. To cite this version: Sylwia Tyrkalska, Ana Pérez-Oliva, Lola Rodríguez-Ruiz, Francisco Martínez-Morcillo, Francisca Alcaraz-Pérez, et al.. Inflammasome Regulates Hematopoiesis through Cleavage of the Mas- ter Erythroid Transcription Factor GATA1. Immunity, Elsevier, 2019, Epub ahead of print. 10.1016/j.immuni.2019.05.005. hal-02148333 HAL Id: hal-02148333 https://hal.archives-ouvertes.fr/hal-02148333 Submitted on 5 Jun 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Manuscript 1 INFLAMMASOME REGULATES HEMATOPOIESIS THROUGH CLEAVAGE 2 OF THE MASTER ERYTHROID TRANSCRIPTION FACTOR GATA1 3 4 Sylwia D. Tyrkalska1,&,#, Ana B. Pérez-Oliva1,#,*, Lola Rodríguez-Ruiz1, Francisco J. 5 Martínez-Morcillo1, Francisca Alcaraz-Pérez2, Francisco J. Martínez-Navarro1, 6 Christophe Lachaud3, Nouraiz Ahmed4, Timm Schroeder4, Irene Pardo-Sánchez1, 7 Sergio Candel1,$, Azucena López-Muñoz1, Avik Choudhuri5, Marlies P. Rossmann5, 8 Leonard I. Zon5,6, María L. Cayuela2, Diana García-Moreno1,*, Victoriano Mulero1,* ,¶ 9 1Universidad de Murcia, IMIB-Arrixaca, Murcia, Spain.
    [Show full text]
  • The Ribosomopathy Paradox
    FEBS Letters 588 (2014) 1491–1500 journal homepage: www.FEBSLetters.org Review Diverse diseases from a ubiquitous process: The ribosomopathy paradox ⇑ Joy Armistead a, Barbara Triggs-Raine a,b, a Department of Biochemistry and Medical Genetics, The University of Manitoba, 745 Bannatyne Ave., Winnipeg, MB R3E 0J9, Canada b The Manitoba Institute of Child Health, 715 McDermot Ave., Winnipeg, MB R3E 3P4, Canada article info abstract Article history: Collectively, the ribosomopathies are caused by defects in ribosome biogenesis. Although these dis- Received 9 January 2014 orders encompass deficiencies in a ubiquitous and fundamental process, the clinical manifestations Revised 8 March 2014 are extremely variable and typically display tissue specificity. Research into this paradox has offered Accepted 12 March 2014 fascinating new insights into the role of the ribosome in the regulation of mRNA translation, cell Available online 19 March 2014 cycle control, and signaling pathways involving TP53, MYC and mTOR. Several common features Edited by Ulrike Kutay of ribosomopathies such as small stature, cancer predisposition, and hematological defects, point to how these diverse diseases may be related at a molecular level. Ó 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. Keywords: Ribosomopathy Ribosome biogenesis Tissue specificity IRES elements 1. Introduction through cleavage and modification events, ensuring equimolar amounts of these rRNA species. The 5S rRNA is transcribed inde- The ribosomopathies are a diverse group of disorders which, pendently by RNA polymerase III in the nucleoplasm, undergoing despite their heterogeneity at a clinical level, affect the same its own maturation pathway before re-importation into the biochemical process.
    [Show full text]